MENS News & Events

Jyong Biotech announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase. Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8's indications to include lipid management, atherosclerosis, and cardiovascular diseases-a strategic move aimed at extending the product's lifecycle and significantly capturing a broader market share. The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including: A statistically significant reduction in total cholesterol levels; A statistically significant increase in serum lactate dehydrogenase levels observed in the placebo group, while no such increase was observed in the MCS-8 group.

Jyong Biotech noted the recent fluctuation in its share price and the increased trading volume of its shares on the Nasdaq Stock Exchange following the expiry of the lock-up period this month. The company said, "The Company has been in ongoing discussions with certain investment funds that are interested in purchasing the Company's ordinary shares. The Company confirms that it is in compliance with its continuous disclosure obligations under the SEC regulations. The Company is not aware of any material, unpublished price-sensitive information or corporate developments that would explain the recent trading activity. The Company's research and development, operation remain solid and its financial condition and results of operations remain consistent with the information disclosed in its most recent public filings, including but not limited to its Current Report on Form 6-K. Jyong Biotech cautions its investors that share price movements can be influenced by various factors, including general market conditions, sector-specific news, and general supply and demand dynamics, which are beyond the Company's control. The Company remains committed to keeping its shareholders informed of all material developments in accordance with applicable laws and regulations."